KLK7

(redirected from hK7)

KLK7

A gene on chromosome 19q13.3 that encodes a serine protease that catalyses the degradation of intercellular cohesive structures in the cornified layer of the skin during the normal shedding of cells from the skin surface. KLK7 may play a role in activating precursors of inflammatory cytokines.
References in periodicals archive ?
3% stakes respectively in China Eastern Airlines, giving them a combined 24% holding valued at HK7.
LEAR SPEAR has been invited to take part in the HK7 million (pounds 590,000) Audemars Piguet QE II Cup at Sha Tin on April 16.
The article referred to Hong Kong's currency board system, which has maintained a foreign exchange rate of HK7.
Aside from the skin, this serine protease is predominantly produced in the esophagus and kidney and is secreted into various bodily fluids, including malignant ascites from ovarian cancer patients (19), where its presence suggests a potential relationship between hK7 and ovarian cancer.
In the present study, we monitored the effects of hormone treatment on serum and urine concentrations of hK2, hK3, hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13, and hK14 in female-to-male transsexuals receiving high-dose testosterone treatment for 4-12 months.
Conversely, antiandrogens plus transdermal estrogens suppressed serum hK4 and hK7 concentrations, but these kallikreins were not suppressed by antiandrogens plus oral estrogens.
Two of the 3 described mRNA variants of human KLK7 (8,10,13) encode full-length hK7 because these mRNAs encompass either of the 2 alternative noncoding 5'-terminal exons 1 and all of the coding exons.
Although other authors have reported that KLK7 mRNA is expressed in ovarian cancer tissues in higher amounts than in controls and reported a relationship with skin diseases (14,15), there has been no report linking hK7 protein with human disease because of a lack of methods for hK7 quantification.
Recombinant hK1, hK2, hK3, hK4, hK5, hK6, hK7, hK8, hK9, hK10, hK11, hK12, hK14, and hK15 proteins did not produce measurable readings, even at concentrations 1000-fold higher than that of hK13.
The cross-reactivities of other homologous proteins were also investigated using recombinant hK1, hK2, hK3, hK4, hK5, hK6, hK7, hK9, hK10, hK11, hK12, hK13, hK14, and hK15, all at a concentration of 1 mg/L (produced in-house).
hK5 is predicted to be able to activate hK7 in the skin (50).
The cross-reactivity of our assay with other kallikreins was determined by the use of purified, recombinant hK2 (250 [micro]g/L), hK3 (PSA; 1000 [micro]g/L), hK5 (1000 [micro]g/L), hK6 (2500 [micro]g/L), hK7 (1000 [micro]g/L), hK8 (1000 [micro]g/L), hK9 (1000 [micro]g/L), hK10 (1000 [micro]g/L), hK11 (1000 [micro]g/L), hK12 (1000 [micro]g/L), hK13 (1000 [micro]g/L), and hK14 (1000 [micro]g/L).